Companies: 10,795·Total market cap: $144.5T
American Healthcare REIT, Inc.

American Healthcare REIT, Inc.

AHRNYSEReal Estate● Active
$45.17
$-2.31(-4.87%)
Market Cap$9.3B
P/E Ratio
52W High$54.67
52W Low$34.273
Overview

American Healthcare REIT, Inc. (AHR) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ahr · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
10
Hold
1
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 90.9%

12-Month Price Target

High

$60.00

Consensus

$57.20

+26.6% upside

Low

$55.00

Median: $57 · Last Close: $45.17

The American Healthcare REIT, Inc. (AHR) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month AHR price target is $57.20, representing +26.6% upside from the current price of $45.17.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $57 (26.6%)

Consensus Target

$57.20

26.6% upside

High Target

$60

32.8%

Low Target

$55

21.8%

Current Price

$45.17

as of today

Based on analyst price targets, the AHR stock price prediction for the next 12 months ranges from $55 to $60. The consensus AHR price forecast of $57.20 implies 26.6% upside from the current price of $45.17.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$43.423.88%

1-day model range: $43.26–$43.58. Peak: $43.58 (-3.88%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$81+80.0%
2028$120+166.4%
2029$155+243.1%
2030$182+302.4%
2031+344.1%
Confidence:MediumCapped at 80% annual limit

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)30.3Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · AHR · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$46.40SELL
MA 10$47.90SELL
MA 20$49.29SELL
MA 50$49.24SELL
MA 100$49.66SELL
MA 200$47.51SELL
Current $AHR · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$46.58SELL
EMA 10$47.52SELL
EMA 20$48.52SELL
EMA 50$49.27SELL
EMA 100$48.95SELL
EMA 200$46.36SELL
Current $AHR · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Keybanc2026-05-28
Maintains
OverweightOverweight
RBC Capital2026-05-26
Maintains
OutperformOutperform
Truist Securities2026-03-13
Maintains
BuyBuy
Scotiabank2026-03-11
Maintains
Sector OutperformSector Outperform
Citigroup2026-03-02
Maintains
NeutralNeutral
Citizens2026-02-05
Maintains
Market OutperformMarket Outperform
Truist Securities2026-01-20
Maintains
BuyBuy
Truist Securities2025-11-26
Maintains
BuyBuy
Citigroup2025-11-21
Maintains
NeutralNeutral
Morgan Stanley2025-11-20
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on American Healthcare REIT, Inc. (AHR) stock. Of the recent 48 rating actions, 0 were upgrades and 0 were downgrades. 11 analysts currently cover AHR.

Analyst Recommendation Trends

Buy ratings22
Hold ratings00
Sell ratings00

AHR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$2.6B

↓ 12.0% YoY

Revenue Next Year

$2.9B

↑ 9.9% YoY

EPS This Year

$0.57

EPS Next Year

$0.81

↑ 42.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AHR EPS of $0.57 for the current fiscal year, based on estimates from 3 analysts. The AHR revenue forecast is $2.6B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The AHR stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AHR price target is $57.20 (+26.6% upside), with an analyst consensus of Buy.

The AHR short-term stock prediction for tomorrow is $43.42 (-3.88%). The AHR stock price prediction for 2027 estimates an average of $81. The AHR stock prediction for 2030 projects a range of $174–$189.

American Healthcare REIT, Inc. trades on NYSE under the ticker AHR. The AHR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 91% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

AHR forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month AHR price target is $57.20, with a high forecast of $60.00 and a low of $55.00. The median price target is shown in the chart above when available. This implies +26.6% potential upside from the current price of $45.17.

AHR price targetWhat is AHR price targetAHR analyst price targetAHR 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.